Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: Mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases

Applied Immunohistochemistry and Molecular Morphology

Volumn 11, Issue 3, 2003, Pages 238-243

  McCarthy, Denis M ^a   Maitra, Anirban ^a   Argani, Pedram ^a   Rader, Anne E ^b   Faigel, Douglas O ^c   Van Heek, N Tjarda ^d   Hruban, Ralph H ^a   Wilentz, Robb E ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Endoscopy; Fine needle aspiration; Immunohistochemical; Mesothelin; Pancreas; Prostate stem cell antigen

Indexed keywords

PROSTATE STEM CELL ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASPIRATION BIOPSY; ASPIRATION CYTOLOGY; CANCER CYTODIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC VALUE; ENDOSCOPY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PAPANICOLAOU TEST; PRIORITY JOURNAL; ULTRASOUND;

EID: 0042316739     PISSN: 15412016     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129039-200309000-00006     Document Type: Article

References (36)

1. Bentz JS, Kochman ML, Faigel DO, et al. Endoscopic ultrasound-guided real-time fine-needle aspirition: clinicopathologic features of 60 patients. Diagn Cytopathol. 1998;18:98-109.
2. Chang KJ, Katz KD, Durbin TE, et al. Endoscopic ultrasound-guided fine-needle aspiration. Gastrointest Endosc. 1994;40:694-9.
3. Itani KMF, Taylor TV, Green LK. Needle biopsy for suspicious lesions of the head of the pancreas: pitfalls and implications for therapy. J Gastrointest Surg. 1997;1:337-41.
4. David O, Green L, Reddy V, et al. Pancreatic masses: a multi-institutional study of 364 fine-needle aspiration biopsies with histopathologic correlation. Diagn Cytopathol. 1998;19:423-7.
5. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997;57:1731-4.
6. Van Es JM, Polak MM, van den Berg FM, et al. Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product. J Clin Pathol. 1995;48:218-22.
7. Dowell SP, Wilson POG, Derias NW, et al. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 1994;54:2914-8.
8. Sturm PD, Rauws EA, Hruban RH, et al. Clinical value of K-ras codon 12 analysis and endobiliary brush cytology for the diagnosis of malignant extrahepatic bile duct stenosis. Clin Cancer Res. 1999;5:629-5.
9. Fukushima N, Suzuki M, Fukayama M. Analysis of K-ras oncogene mutation directly applied to atypical cell clusters on cytologic smear slides of bile and pancreatic juice. Pathol Int. 1998;48:33-40.
10. Iwao T, Itoh M, Tsuchida A, et al. Detection of p53 protein in cytological specimens of pancreatic diseases obtained by selective endoscopic brushing. Gastroenterology. 1995;108:a361.
11. Dillon DA, Johnson CC, Topazian MD, et al. The utility of K-ras mutation analysis in the cytologic diagnosis of pancreatobiliary neoplasms. Cancer J. 2000;6:299-306.
12. Sturn PDJ, Hruban RH, Ramsoekh TB, et al. The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol. 1998;186:247-53.
13. Tascilar M, Sturm PDJ, Caspers E, et al. Diagnostic p53 immunostaining of endobiliary brush cytology: preoperative cytology compared with the surgical specimen. Cancer. 1999;87:306-11.
14. Apple SK, Hecht JR, Novak JM, et al. Polymerase chain reaction-based K-ras mutation detection of pancreatic adenocarcinoma in routine cytology of pancreatic juice. Am J Clin Pathol. 1996;105:321-6.
15. Uehara H, Nakaizumi A, Baba M, et al. Diagnosis of pancreatic cancer by K-ras point mutation and cytology of pancreatic juice. Am J Gastroenterol. 1996;91:1616-21.
16. van Heek NT, Rader AE, Offerhaus GJA, et al. K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirations of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol. 2002;117:755-65.
17. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-8.
18. Argani P, Rosty C, Reiter RE, et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 2001;61:4320-4.
19. Reiter RE, Gu Z, Watabe T, et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A. 1998;95:1735-40.
20. Gu Z, Thomas G, Yamashiro J, et al. Prostate stem cell antigen (PSCA) expression increases with high Gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene. 2000;19:1288-96.
21. Amara N, Palapattu GS, Schrage M, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 2001;61:4660-5.
22. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93:136-40.
23. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992;50:373-81.
24. Chowdhury PS, Viner JL, Beers R, et al. Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A. 1998;95:669-74.
25. Hassan R, Viner JL, Wang QC, et al. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother. 2000;23:473-9.
26. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995;270:21984-90.
27. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A. 1999;96:11531-6.
28. Faigel DO, Ginsburg GG, Bentz JS, et al. Endoscopic ultrasound-guided fine-needle aspiration biopsy of the pancreas in cancer patients with pancreatic lesions. J Clin Oncol. 1997;15:1439-43.
29. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res. 1996;56:2527-30.
30. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-3.
31. Hahn SA, Hoque ATMS, Moskaluk CA, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996;56:490-4.
32. Hoque AT, Hahn SA, Schutte M, et al. DPC4 gene mutation in colitis associated neoplasia. Gut. 1997;40:120-2.
33. Hahn SA, Bartsch D, Schroers A, et al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res. 1998;58:1124-6.
34. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumor suppressor genes on chromosome 18 in colorectal cancers. Nat Genet. 1996;13:343-6.
35. Takagi Y, Kohmura H, Futamura M, et al. Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. Gastroenterology 1996;111:1369-72.
36. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL, et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol. 2002;160:1239-49.